Overall, our study has not only identified a novel combination of phenformin with MEK inhibition for KRAS-mutant NSCLC, it also provides proof of concept that dual targeting of an oncogenic growth signal and cancer metabolism can be a novel and fruitful approach to achieve steady and significant tumor suppression. The gene discussed is KRAS; the disease is cancer.